Emiliem, Inc. and MIR Preclinical Services (MIR) announce the signing of an agreement whereby MIR will conduct broad preclinical services for Emiliem on its multi-kinase inhibitors created through its K-STAR technology.

The agreement includes preclinical oncology assessments and evaluations of Emiliem's novel anti-tumour agents using xenograft, orthotopic and transgenic animal models.

Dale E. Johnson, Pharm.D., Ph.D., president and CEO of Emiliem, stated "We are extremely pleased to form this relationship with MIR whose expertise and technologies will be instrumental for our quest to create innovative clinical drug development candidates. MIR employs a wide array of novel imaging technologies in its preclinical models to measure response to therapy at anatomical, functional and molecular levels. Many of these imaging technologies can be translated into clinical benchmarks which will eventually speed our evaluation of therapeutic response in cancer patients."

"We are eager to apply our technologies and drug discovery experience to the development of Emiliem's novel compounds", stated Dr. W. R. Leopold, President and CEO of MIR Preclinical Services. "We especially enjoy working closely with our clients, as an extension of their drug discovery effort. We look forward to working with Emiliem to select and characterize novel drug candidates for clinical trials."

Emiliem, Inc. is a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs. The Company has developed proprietary drug design technologies that facilitate the inclusion of multiple kinase inhibitor profiles into single compounds.